Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron Touts Potential Of Growing Eylea Franchise After Robust Q4

This article was originally published in The Pink Sheet Daily

Executive Summary

Speaking at the J.P. Morgan meeting in January, Regeneron CEO Leonard Schleifer says the company is exploring many opportunities to build the franchise around its successful wet AMD drug Eylea. In the fourth quarter, the drug racked up $400 million in U.S. sales, beating expectations.

You may also be interested in...



Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds

Regeneron Pharmaceuticals Inc. executives emphasized the blockbuster potential of product candidates in the company's late-stage research and development pipeline on Aug. 4, while noting that the top-selling biologic Eylea (aflibercept) is facing increased reimbursement and competitive pressures.

Deal Watch: Bristol Places Early Wager On Padlock's Autoimmune Potential

Regeneron and Bayer look to build on their past success collaborating in ophthalmology by partnering to develop an Eylea successor. Sun Pharma builds its portfolio with 13 products from Novartis.

Regeneron/Bayer Partnership Seeks To Build Upon Eylea's Success

Latest ophthalmologic collaboration between the partners seeks to create an Eylea successor by combining aflibercept with an Ang2 antibody.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS076395

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel